Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 11/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | WRN | Q14191 | 1/20 | 0.46 |
| ▸ | FLT3 | P36888 | 7/20 | 0.45 |
| ▸ | CSF1R | P07333 | 4/20 | 0.45 |
| ▸ | FLT1 | P17948 | 4/20 | 0.45 |
| ▸ | FLT4 | P35916 | 4/20 | 0.45 |
| ▸ | RET | P07949 | 2/20 | 0.45 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.45 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.45 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.45 |
| ▸ | FRK | P42685 | 1/20 | 0.45 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.45 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.45 |
| ▸ | HIPK4 | Q8NE63 | 1/20 | 0.45 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.43 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.42 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.42 |
| ▸ | LTK | P29376 | 1/20 | 0.42 |
| ▸ | CDK8 | P49336 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3581862 | 0.94 | KDR (0.48) | KDRBLMWRNFLT3CSF1R | |
| SCHEMBL3579515 | 0.93 | KDR (0.47) | KDRBLMWRNFLT3CSF1R | |
| SCHEMBL3586253 | 0.92 | KDR (0.47) | KDRBLMWRNFLT3CSF1R | |
| SCHEMBL3581507 | 0.90 | KDR (0.51) | KDRBLMRIPK1BRAFRAF1 | |
| SCHEMBL3576165 | 0.88 | GRIK1 (0.48) | KDRFLT3CSF1RFLT1FLT4 | |
| SCHEMBL5469601 | 0.88 | KDR (0.46) | KDRBLMWRNFLT3CSF1R | |
| SCHEMBL3584713 | 0.87 | MTOR (0.41) | KDRFLT3CSF1RFLT1FLT4 | |
| SCHEMBL3579491 | 0.86 | PSEN1 (0.47) | KDRFLT3CSF1RFLT1FLT4 | |
| SCHEMBL3577053 | 0.86 | KDR (0.51) | KDRFLT3CSF1RFLT1FLT4 | |
| SCHEMBL1463403 | 0.86 | KDR (0.45) | KDRBLMWRNFLT3CSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070293553-A1 | Diphenylurea Derivatives Useful As Potassium Channel Activators | NEUROSEARCH A/S (DK) | 2007-12-20 | — | — | US | claimed |
| US-20060178413-A1 | Diphenylurea derivatives and their use as chloride channel blockers | NEUSEARCH A/S (DK) | 2006-08-10 | — | — | US | claimed |
| US-7691891-B2 | Diphenylurea derivatives and their use as chloride channel blockers | NEUROSEARCH A/S (DK) | 2010-04-06 | — | — | US | disclosed |
| US-20070293553-A1 | Diphenylurea Derivatives Useful As Potassium Channel Activators | NEUROSEARCH A/S (DK) | 2007-12-20 | — | — | US | disclosed |
| US-20060178413-A1 | Diphenylurea derivatives and their use as chloride channel blockers | NEUSEARCH A/S (DK) | 2006-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293553-A1 | Diphenylurea Derivatives Useful As Potassium Channel Activators | KCNJ2, KCNH2, KCNH3 | KDR 1142/4885BLM 4646/4885WRN 4582/4885 |
| US-20060178413-A1 | Diphenylurea derivatives and their use as chloride channel blockers | CLIC1, CLIC4, CLCN2 | KDR 2480/4885BLM 3286/4885WRN 4153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.